12:00 PM EST - Oncolytics Biotech® Inc. : Announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo® (nivolumab) to treat relapsed multiple myeloma patients. Oncolytics Biotech® Inc.
shares T.ONC are trading up $0.09 at $2.84.
